Multiplate® GpIIb/IIIa Antagonist Reagent

Multiplate® GpIIb/IIIa Antagonist Reagent frontview

Multiplate® GpIIb/IIIa Antagonist Reagent

The reagent is intended for use as quality control in platelet function testing with whole blood samples on the Multiplate® analyzer. The reagent is employed in combination with the Multiplate® activating reagent TRAPtest. Addition of GpIIb/IIIa Antagonist Reagent to a blood sample leads to strongly reduced aggregation in the TRAPtest and diminished aggregation in Multiplate® tests. This allows the assessment of a positive control (strongly inhibited aggregation).1

Background

In vitro platelet aggregation by electrical impedance relies on recruitment of platelets to a surface (electrode wire) by means of platelet-fibrinogen bonds in order to measure a response. The introduction of a substance that blocks the binding of fibrinogen to the resting or activated GPIIb/IIIa receptor will result in reduced or absent platelet aggregation to all agonists1,2 including TRAP-6.

References
  1. Desch, S., Siegemund, A., Scholz, U., et al. (2011). Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Clin Res Cardiol. Oct 21.
  2. Penz, S., Perchuc, A., Calatzis, A., et al. (2010). Effects of GpIIbIIIa and GpIb blockade on multiple electrode aggregometry (MEA). GTH; Abstract P10-13.